The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study
Abstract
Purpose: Patients with relapsed or refractory chronic lymphocytic leukemia (CLL) have profound immune defects and limited treatment options. Given the dramatic activity of lenalidomide in other B-cell malignancies and its pleotropic immunomodulatory effects, we conducted a phase II trial of this agent in CLL. Patients and Methods: Patients with relapsed or refractory B-cell CLL (B-CLL) were eligible if they required treatment as per the National Cancer Institute Working Group 1996 guidelines. Lenalidomide was administered orally at 25 mg on days 1 through 21 of a 28-day cycle. Response was assessed after each cycle. Patients were to continue treatment until disease progression, unacceptable toxicity, or complete remission. Rituximab was added to lenalidomide on disease progression. Results: Forty-five patients were enrolled, with a median age of 64 years. Sixty-four percent of the patients had Rai stage III or IV disease, and 51% were refractory to fludarabine. The overall response rate was 47%, with 9% of the patients attaining a complete remission. Fatigue, thrombocytopenia, and neutropenia were the most common adverse effects noted in 83%, 78%, and 78% of the patients, respectively. Conclusion: Lenalidomide is clinically active in patients with relapsed or refractory B-CLL. These findings are encouraging and warrant further investigation of this agent in the treatment of this disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical staging of chronic lymphocytic leukemia
Rai, K., Sawitsky, A., Cronkite, E., Chanana, A., Levy, R., & Pasternack, B. (1975) · Blood · doi:10.1182/blood.v46.2.219.219 · Cited by 2,784
Cheson, B., Bennett, J., Grever, M., Kay, N., Keating, M., O'Brien, S., & Rai, K. (1996) · Blood · doi:10.1182/blood.v87.12.4990.bloodjournal87124990 · Cited by 1,819
Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., Marcé, S., López-Guillermo, A., Campo, E., & Montserrat, E. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023143 · Cited by 1,055
Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
Rai, K. R., Peterson, B. L., Appelbaum, F. R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G. A., Larson, R. A., Cheson, B. D., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012143432402 · Cited by 1,001
Keating, M. J., O’Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Faderl, S., Thomas, D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.051 · Cited by 950
Efficacy of Lenalidomide in Myelodysplastic Syndromes
List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Byrd, J. C. (2003) · Blood · doi:10.1182/blood-2002-04-1258 · Cited by 571
Wierda, W., O’Brien, S., Wen, S., Faderl, S., Garcia-Manero, G., Thomas, D., Do, K.-A., Cortes, J., Koller, C., Beran, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.516 · Cited by 524
Lagneaux, L., Delforge, A., Bron, D., De Bruyn, C., & Stryckmans, P. (1998) · Blood · doi:10.1182/blood.v91.7.2387 · Cited by 413
Byrd, J. C. (2005) · Blood · doi:10.1182/blood-2004-03-0796 · Cited by 404
Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?
Korn, E. L., Arbuck, S. G., Pluda, J. M., Simon, R., Kaplan, R. S., & Christian, M. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.265 · Cited by 331
B-Cell Chronic Lymphocytic Leukemia: A Bird of a Different Feather
Caligaris-Cappio, F., & Hamblin, T. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.399 · Cited by 321
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells
Görgün, G., Holderried, T. A. W., Zahrieh, D., Neuberg, D., & Gribben, J. G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24176 · Cited by 298
Dredge, K., Horsfall, R., Robinson, S. P., Zhang, L.-H., Lu, L., Tang, Y., Shirley, M. A., Muller, G., Schafer, P., Stirling, D., et al. (2005) · Microvascular Research · doi:10.1016/j.mvr.2005.01.002 · Cited by 268
Panayiotidis, P., Jones, D., Ganeshaguru, K., Foroni, L., & Hoffbrand, A. V. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.00305.x · Cited by 264
Byrd, J. C., Gribben, J. G., Peterson, B. L., Grever, M. R., Lozanski, G., Lucas, D. M., Lampson, B., Larson, R. A., Caligiuri, M. A., & Heerema, N. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1021 · Cited by 257
Bartlett, J. B., Michael, A., Clarke, I., Dredge, K. S., Nicholson, S., Kristeleit, H., Polychronis, A., Pandha, H. S., Muller, G. W., Stirling, D., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601579 · Cited by 143
B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules
Kay, N. E., Bone, N. D., Tschumper, R., Howell, K., Geyer, S., Dewald, G., Hanson, C., & Jelinek, D. (2002) · Leukemia · doi:10.1038/sj.leu.2402467 · Cited by 135
Chanan-Khan, A. A., Miller, K. C., Takeshita, K., Koryzna, A., Donohue, K. A., Bernstein, Z. P., Mohr, A., Klippenstein, D. L., Wallace, P. K., Zeldis, J. B., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0669 · Cited by 104
Self-citationImpairments in immune cell function in B cell chronic lymphocytic leukemia.
Bartik, M. M., Welker, D., & Kay, N. E. (1998) · PubMed · Cited by 103
Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide
Bartlett, J. B., Tozer, A., Stirling, D., & Zeldis, J. B. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602774 · Cited by 71
Autocrine and paracrine growth loops in chronic lymphocytic leukemia.
Hoffbrand, A. V., Panayiotidis, P. G., Reittie, J. E., & GANESHAGURU, K. (1993) · PubMed · Cited by 53
Trentin, L., Zambello, R., Agostini, C., et al. (1994) · Blood · doi:10.1182/blood.v84.12.4249.bloodjournal84124249 · Cited by 52
Mitsiades, C. S., & Mitsiades, N. (2004) · PubMed · Cited by 47
Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience
Barlogie, B. (2003) · Seminars in Hematology · doi:10.1053/j.seminhematol.2003.09.005 · Cited by 35
TNF Receptors in Chronic Lymphocytic Leukemia
Waage, A., & Espevik, T. (1994) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199409051650 · Cited by 22
The angiogenic status of B-CLL B cells: role of the VEGF receptors
Kay, N. E. (2003) · Leukemia Research · doi:10.1016/j.leukres.2003.10.014 · Cited by 16
Cited by
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Ramsay, A. G., Johnson, A. J., Lee, A. M., Gorgün, G., Le Dieu, R., Blum, W., Byrd, J. C., & Gribben, J. G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35017 · Cited by 600
Brown, J. R., Byrd, J. C., Coutre, S. E., Benson, D. M., Flinn, I. W., Wagner-Johnston, N. D., Spurgeon, S. E., Kahl, B. S., Bello, C., Webb, H. K., et al. (2014) · Blood · doi:10.1182/blood-2013-11-535047 · Cited by 590
Cheson, B. D., Ansell, S., Schwartz, L., Gordon, L. I., Advani, R., Jacene, H. A., Hoos, A., Barrington, S. F., & Armand, P. (2016) · Blood · doi:10.1182/blood-2016-05-718528 · Cited by 521
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment
Hallek, M. (2019) · American Journal of Hematology · doi:10.1002/ajh.25595 · Cited by 504
Metadata
- Authors
- Chanan-Khan, A., Miller, K. C., Musial, L., Lawrence, D., Padmanabhan, S., Takeshita, K., Porter, C. W., Goodrich, D. W., Bernstein, Z. P., Wallace, P., Spaner, D., Mohr, A., Byrne, C., Hernandez-Ilizaliturri, F., Chrystal, C., Starostik, P., & Czuczman, M. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-12-01
- Volume
- 24
- Issue
- 34
- Pages
- 5343-5349
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2136242714
- Cited by
- 414
- References
- 29
- FWCI
- 13.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.